[ is distinct conversations ]. And live here this morning on c spann span 3, a discussion about transparency and oversight at the food and Drug Administration. Well be hearing from dr. Scott gottlieb starting off the conference. Introductions under way. Efforts to pass and implement the food safety modernization act, focus on medical devices, especially the potential of using the unique device identifier to improve monitoring devices throughout the product lifecycle. We have successfully worked on products 10 to courage innovation particularly around antibiotics and 10 to sure appropriate use of them. We focused on drug safety and transparency in the supply chain and especially on the safety of compounded drugs. Among other things, pew submitted transparency to the task force back in 2010 if the. They touch on some of the topics well be discussing today. Reading the background papers for todays meet regular mind med of a meeting we convened in a room directly above of us here a few yea
Thank you so much for coming. Thank you. I forgot to turn my mike on. Jonathan is a partner with deerfield management and chairman of the deerfield institute. He joined this company in 2013. The company focuses on Venture Capital and structured investments and Bio Technology and pharmaceuticals. Prior to joining deerfield for more than 16 years, jonathan was with Warburg Pincus where he led investment in Bio Technology and pharmaceuticals. Hes been active in policy discussions related to health care and medical innovation and served on the executive committee of the board of the national Venture Capital association and led that groups Life Sciences efforts. He has also served on the emerging Company Section board of the Bio Technology industry organization. He has served on many related nonprofit boards including the reagan ucall foundation for the food and Drug Administration. He is a graduate of Harvard University and the Stanford School of business and we thank you for coming. Thank